BMC Nephrology (Jan 2013)

Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study

  • Nakayama Masaru,
  • Kaizu Yoshiki,
  • Nagata Masaharu,
  • Ura Yoriko,
  • Ikeda Hirofumi,
  • Shimamoto Sho,
  • Kuma Kazuyoshi

DOI
https://doi.org/10.1186/1471-2369-14-22
Journal volume & issue
Vol. 14, no. 1
p. 22

Abstract

Read online

Abstract Background Fibroblast growth factor 23 (FGF23) is an important hormone in the regulation of phosphate metabolism. It is unclear whether FGF23 is associated with carotid artery calcification (CAAC) in predialysis patients. The present study aimed to clarify the relationship between FGF23 and CAAC in patients with chronic kidney disease (CKD) who were not on dialysis. Methods One-hundred ninety-five predialysis CKD patients were enrolled in this cross-sectional study. CAAC was assessed using multidetector computed tomography, and the prevalence of CAAC was examined. Intact FGF23 was measured in each patient. The risk factors for CAAC were evaluated using a logistic regression model. Results We found CAAC in 66% of the patients. The prevalence of CAAC significantly increased across CKD stages: it was 37% in CKD stages 1–2, 58% in stage 3; 75% in stage 4, and 77% in stage 5 (p Conclusions The prevalence of CAAC is increased with the decline in the kidney function. FGF23 is independently related to CAAC in patients with CKD who are not on dialysis.

Keywords